Johnson & Johnson secured approval from the National Medical Products Administration in China for its muscle-disorder treatment, nipocalimab. The drug, acquired via a $6.5 billion buyout of Momenta in 2020, targets generalized myasthenia gravis in patients 12 and older. J&J expects the treatment to generate blockbuster revenue as it expands into a market already occupied by three major competitors.

Expanding the Blockbuster Portfolio